ArticleActa neurochirurgica2025
Management of acromegaly beyond primary surgery: efficacy and safety of repeat surgery and radiotherapy.
Article in Acta neurochirurgica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introduction and purposeRe-intervention, either transsphenoidal surgery or radiotherapy, is suggested in patients who are not in remission after primary surgery for acromegaly; however, the evidence is weak. We aimed to assess the remission rate after re-intervention, and complications compared to a comparison group who had undergone primary interventions only.
methodsPatients diagnosed with acromegaly between 2005-2021 at Oslo University Hospital were screened for inclusion. The study cohort included patients with two or more interventions. The comparison group included patients not in remission after primary surgery.
resultsOf 223 patients with acromegaly, 42 underwent re-interventions (study cohort). At diagnosis, median age was 38 (IQR 29-48) years and 41 patients (98%) had a macroadenoma. The comparison group consisted of 49 patients, median age 54 (IQR 44-60) years and 37 (76%) had a macroadenoma at diagnosis. Re-interventions in the study cohort consisted of surgery, radiotherapy and a combination of these (22, 12 and eight patients). After re-interventions, 22 patients (52%) were in remission and 12 (29%) had reduced disease activity. Seven patients (17%) acquired new hormone deficiencies, two of them corticotroph deficiency. One patient in remission developed spinal fluid leakage and meningitis. There was no significant difference in complications after surgery between the study cohort and the comparison group.
conclusionRe-interventions were safe and resulted in remission or substantial improvement in most patients. Re-intervention should be considered for patients who would otherwise require lifelong medical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.